Nasdaq

Perspective Therapeutics Advances [212Pb]VMT-α-NET Phase 1/2a Study to Cohort 3 with Higher Dosing Strategy

Perspective Therapeutics, Inc. announced that its Phase 1/2a clinical trial for [212Pb]VMT-α-NET is moving into Cohort 3, administering a higher fixed dose of 6 mCi for patients with unresectable or ...
Yahoo Finance

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium ...

SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ...
Nasdaq

Perspective Therapeutics Provides Updated Interim Results and Safety Findings for [212Pb]VMT-α-NET at ASCO 2025

Perspective Therapeutics, Inc. presented updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting, showing a favorable safety profile with ...
Morningstar

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in ...
Seeking Alpha

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Greetings. Welcome to VMT-alpha-NET update at ESMO. [Operator Instructions]. Please note that this conference is being recorded. At this time, I'll now turn the conference over to Annie Cheng, Vice ...